Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept, rituximab or tocilizumab3件: Abatacept,
Rituximab,
Tocilizumab		3件: D02596 ,
D02994 (Name: Rituximab),
D03203 		4件: CD80,
CD86,
IL6R,
MS4A1 💬		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46
2ABP 798 - Biosimilar to rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
3ABP 798 Biosimilar to Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
4Administration of rituximab and methylprednisolone2件: Methylprednisolone,
Rituximab		2件: D00407 ,
D02994 (Name: Rituximab)		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 51
5Alemtuzumab and Rituximab2件: Alemtuzumab,
Rituximab		2件: D02802 ,
D02994 (Name: Rituximab)		2件: CD52,
MS4A1 💬		2件: , Hematopoietic cell lineage 💬1件: 60
6Alemtuzumab, Rituximab2件: Alemtuzumab,
Rituximab		2件: D02802 ,
D02994 (Name: Rituximab)		2件: CD52,
MS4A1 💬		-1件: 63
7Belimumab in SLE patients / Rituximab in RA patients2件: Belimumab,
Rituximab		2件: D02994 (Name: Rituximab),
D03068 		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
8Bendamustine, Rituximab2件: Bendamustine,
Rituximab		2件: D02994 (Name: Rituximab),
D07501 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
9Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine3件: Azathioprine,
Dexamethasone,
Rituximab		3件: D00238 ,
D00292 ,
D02994 (Name: Rituximab)		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 35
10Combination of Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63
11Combination of Rituximab with subcutaneous belimumab2件: Belimumab,
Rituximab		2件: D02994 (Name: Rituximab),
D03068 		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 63
12Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85
13Cyclophosphamide/Rituximab2件: Cyclophosphamide,
Rituximab		3件: D00287 ,
D02994 (Name: Rituximab),
D07760 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
14Dexamethasone and Rituximab2件: Dexamethasone,
Rituximab		2件: D00292 ,
D02994 (Name: Rituximab)		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63
15Double-Blind Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 51
16Dr. Reddy’s Rituximab (DRL_RI) 100mg1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
17Dr. Reddy’s Rituximab (DRL_RI) 500mg1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
18Eltrombopag combining rituximab2件: Eltrombopag,
Rituximab		1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63
19Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab		4件: D02596 ,
D02994 (Name: Rituximab),
D03203 ,
D10161 		4件: CD80,
CD86,
IL6R,
MS4A1 💬		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46
20Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222
21GP2013 - A Proposed biosimilar rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
22IDEC-C2B8 (rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
23Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64
24Individualized dose of rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49
25Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		10件: D01370 ,
D02802 ,
D02994 (Name: Rituximab),
D03846 ,
D05218 ,
D06886 ,
D09314 ,
D10001 ,
D10172 ,
D11215 		7件: CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		-1件: 13
26Intravenous Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 66
27MabionCD20 (candidate biosimilar to rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
28MabThera (Rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬4件: 13, 46, 49, 53
29Mabthera or biosimilar Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
30Mabthera or biosimilar rituximab product1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
31MabThera® (rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
32Originator rituximab - Rituxan ® or MabThera ®1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
33Perfusion of treatment Rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
34Prednisone, low dose rituximab2件: Prednisone,
Rituximab		2件: D00473 ,
D02994 (Name: Rituximab)		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 61
35RhTPO in combination with Rituximab2件: Recombinant Human Thrombopoietin,
Rituximab		1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63
36Rituxan (INN: Rituximab), brand name in the United States1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
37Rituxan (INN: Rituximab), brand name in the US1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
38Rituxan (rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49
39Rituxan® (rituximab)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
40RITUXIMAB1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
41Rituximab (anti-CD20)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 53
42Rituximab (Arm A)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44
43Rituximab (Arm B)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44
44Rituximab (EU)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
45Rituximab (genetical recombination)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 14
46Rituximab (MABTHERA® or RITUXAN®).1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 35, 61
47Rituximab (Mabthera®)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
48Rituximab (Rituxan)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 11
49Rituximab (RTX) and Azathioprine (AZA)2件: Azathioprine,
Rituximab		2件: D00238 ,
D02994 (Name: Rituximab)		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 65
50Rituximab (US)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
51Rituximab - MabThera1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
52Rituximab 1g IV1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 162
53Rituximab [MabThera/Rituxan]1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 46, 63
54Rituximab [MabThera]1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
55Rituximab and Cyclophosphamide IV2件: Cyclophosphamide,
Rituximab		3件: D00287 ,
D02994 (Name: Rituximab),
D07760 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 35
56Rituximab and Hyaluronidase Human2件: Hyaluronidase,
Rituximab		4件: D02994 (Name: Rituximab),
D04455 ,
D04456 ,
D06604 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 331
57Rituximab combined with Omalizumab2件: Omalizumab,
Rituximab		2件: D02994 (Name: Rituximab),
D05251 		2件: FCER1A,
MS4A1 💬		5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162
58Rituximab combined with tacrolimus induction + rituximab maintenance2件: Rituximab,
Tacrolimus		3件: D00107 ,
D02994 (Name: Rituximab),
D08556 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222
59Rituximab combined with tacrolimus induction + tacrolimus maintenance2件: Rituximab,
Tacrolimus		3件: D00107 ,
D02994 (Name: Rituximab),
D08556 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222
60Rituximab Infusion1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 13, 222
61Rituximab IT1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
62Rituximab IV1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
63Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
64Rituximab MabThera1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
65Rituximab, Cyclophosphamide, and Corticosteroids2件: Cyclophosphamide,
Rituximab		3件: D00287 ,
D02994 (Name: Rituximab),
D07760 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222
66Rituximab, Mabthera1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 53
67Rituximab, MTX, folic acid2件: Folic acid,
Rituximab		2件: D00070 ,
D02994 (Name: Rituximab)		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
68Rituximab, observational study amon patients with active RA1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
69Rituximab-EU+ Rituximab-Pfizer x 2 Courses1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
70Rituximab-Pfizer1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
71Rituximab-Pfizer (PF-05280586) x 3 courses1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
72Rituximab-US + Rituximab-Pfizer x 2 Courses1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
73Rituximab/ Mabthera1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 271
74SAIT101 (proposed rituximab biosimilar)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
75SAIT101 (rituximab biosimilar)1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
76Standard dose of rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49
77The Standard Steroid Treatment, Plasma Exchange and rituximab1件: Rituximab1件: D02994 (Name: Rituximab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85